Drug Trial Radar · NCT02564523
Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
Last checked: Nov 19, 2026Latest source record: Mar 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,075
Actual
Start
Nov 6, 2015
Primary completion
Feb 12, 2019
Study completion Feb 12, 2019
Sponsor
- Lead sponsor
- Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- EBOVAC2 Consortium; Institut National de la Santé Et de la Recherche Médicale, France; Centre Muraz
- First posted
- Sep 30, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 4 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and immunogenicity of three heterologous prime-boost regimens for Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo. The study will include healthy adults and elderly participants, HIV infected participants and healthy children in 2 age strata.
Conditions
- Hemorrhagic Fever, Ebola
Interventions
Ad26.ZEBOVBiological
One 0.5 mL intramuscular (IM) injection of (5x10\*10 viral particles)
MVA-BN-FiloBiological
One 0.5 mL IM injection of (1x10\*8 infectious units)
PlaceboBiological
One 0.5 mL IM injection of 0.9% saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (Day 29)Time frame: Up to 28 days post-dose 1 (Day 29)
- Number of Participants With Adverse Events (AEs) (28-Day Interval)Time frame: Up to 28 days post-dose 2 (Day 57 for Cohorts 1, 2a, 2b and 3 [28-Day Interval])
- Number of Participants With Adverse Events (56-day Interval)Time frame: Up 28 days post-dose 2 (Day 85 for Cohorts 1, 2a, 2b and 3 [56-Day Interval])
- Number of Participants With Adverse Events (84-day Interval)Time frame: Up to 28 days post-dose 2 (Day 113 for Cohort 1 [84-Day Interval])
- Number of Participants With Adverse Events Post-dose 3 (Day 393)Time frame: Up 28 days post-dose 3 (Day 393)
- Number of Participants With Serious Adverse EventsTime frame: Up to 3 years and 3 months
- Number of Participants With Immediate Reportable Events (IREs)Time frame: Up to 3 years and 3 months
- Number of Participants With Solicited Local Adverse Events (Day 8)Time frame: 7 days post-dose 1 (Day 8)
- Number of Participants With Solicited Local Adverse Events (28-day Interval)Time frame: Up to 7 days post-dose 2 (Day 36 for Cohort 1, 2a, 2b and 3 [28-Day Interval])
- Number of Participants With Solicited Local Adverse Events Post-dose 2 (56-day Interval)Time frame: Up to 7 days post-dose 2 (Day 64 for Cohort 1, 2a, 2b and 3 [56-Day Interval])
- Number of Participants With Solicited Local Adverse Events (84-day Interval)Time frame: Up to 7 days post-dose 2 (Day 92 for Cohort 1 [84-Day Interval])
- Number of Participants With Solicited Local Adverse Events (Day 372)Time frame: Up 7 days post-dose 3 (Day 372)
- Number of Participants With Solicited Systemic Adverse Events (Day 8)Time frame: Up to 7 days post-dose 1 (Day 8)
- Number of Participants With Solicited Systemic Adverse Events (28-Day Interval)Time frame: Up to 7 days post-dose 2 (Day 36 for Cohorts 1, 2a, 2b and 3 [28-Day Interval])
- Number of Participants With Solicited Systemic Adverse Events (56-Day Interval)Time frame: Up 7 days post-dose 2 (Day 64 for Cohort 1, 2a, 2b and 3 [56-Day Interval])
- Number of Participants With Solicited Systemic Adverse Events (84-Day Interval)Time frame: Up 7 days post-dose 2 (Day 92 for Cohort 1 [84-Day Interval])
- Number of Participants With Solicited Systemic Adverse Events (Day 372)Time frame: Up to 7 days post-dose 3 (Day 372)
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
BoboDioulasso, Burkina Faso
Site not named
Ouagadougou, Burkina Faso
Site not named
Abidjan, Côte d’Ivoire
Site not named
Toupah/Ousrou, Côte d’Ivoire
Site not named
Nairobi, Kenya
Site not named
Entebbe, Uganda
Site not named
Kampala, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.